First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
W. R. Schelman
No relevant relationships to disclose
S. K. Sandhu
No relevant relationships to disclose
V. Moreno Garcia
No relevant relationships to disclose
G. Wilding
No relevant relationships to disclose
L. Sun
Employment or Leadership Position - Merck
C. Toniatti
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
M. Stroh
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
N. Kreischer
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
C. L. Carpenter
Employment or Leadership Position - Merck
Stock Ownership - Merck Sharp & Dohme
L. R. Molife
No relevant relationships to disclose
S. B. Kaye
No relevant relationships to disclose
J. S. De Bono
No relevant relationships to disclose
R. M. Wenham
No relevant relationships to disclose